Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

[Angiotensin converting enzyme and Alzheimer's disease].

Kugaevskaia EV.

Biomed Khim. 2013 Jan-Feb;59(1):5-24. Review. Russian.

PMID:
23650720
2.

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

Kehoe PG, Wilcock GK.

Lancet Neurol. 2007 Apr;6(4):373-8. Review.

PMID:
17362841
3.
4.

[Novel Abeta-converting activity of angiotensin-converting enzyme and its role in Alzheimer's disease].

Zou K, Michikawa M, Komano H.

Seikagaku. 2010 Dec;82(12):1120-4. Review. Japanese. No abstract available.

PMID:
21348266
5.

[Angiotensin converting enzyme: the antigenic properties of the domain, role in Alzheimer's disease and tumor progression].

Kugaevskaya EV, Timoshenko OS, Solovyeva NI.

Biomed Khim. 2015 May-Jun;61(3):301-11. doi: 10.18097/PBMC20156103301. Review. Russian.

PMID:
26215407
6.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
7.

The brain RAS and Alzheimer's disease.

Wright JW, Harding JW.

Exp Neurol. 2010 Jun;223(2):326-33. doi: 10.1016/j.expneurol.2009.09.012. Epub 2009 Sep 24. Review.

PMID:
19782074
8.

STRUCTURAL CHARACTERISTICS AND ANTIHYPERTENSIVE EFFECTS OF ANGIOTENSIN-I-CONVERTING ENZYME INHIBITORY PEPTIDES IN THE RENIN-ANGIOTENSIN AND KALLIKREIN KININ SYSTEMS.

Manoharan S, Shuib AS, Abdullah N.

Afr J Tradit Complement Altern Med. 2017 Jan 13;14(2):383-406. doi: 10.21010/ajtcam.v14i2.39. eCollection 2017. Review.

9.

[Angiotensin converting enzyme domain structure and properties].

Kugaevskaia EV.

Biomed Khim. 2005 Nov-Dec;51(6):567-80. Review. Russian.

PMID:
16521820
10.

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N.

Expert Rev Neurother. 2009 Sep;9(9):1413-31. doi: 10.1586/ern.09.89. Review.

PMID:
19769454
11.
12.

Kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo.

Viel TA, Buck HS.

Curr Alzheimer Res. 2011 Feb;8(1):59-66. Review.

PMID:
21143155
13.

[Involvement of beta-amyloid in the etiology of Alzheimer's disease].

Tomiyama T.

Brain Nerve. 2010 Jul;62(7):691-9. Review. Japanese.

PMID:
20675873
14.

Impact of kinins in the treatment of cardiovascular diseases.

Regoli D, Plante GE, Gobeil F Jr.

Pharmacol Ther. 2012 Jul;135(1):94-111. doi: 10.1016/j.pharmthera.2012.04.002. Epub 2012 Apr 17. Review.

PMID:
22537664
15.

The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.

Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T.

J Cardiovasc Pharmacol. 1994;24 Suppl 2:S6-13. Review.

PMID:
7898096
16.
17.

The renin-angiotensin system and its blockers.

Igić R, Škrbić R.

Srp Arh Celok Lek. 2014 Nov-Dec;142(11-12):756-63. Review.

18.

The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?

Kehoe PG, Passmore PA.

J Alzheimers Dis. 2012;30 Suppl 2:S251-68. doi: 10.3233/JAD-2012-111376. Review.

PMID:
22330821
19.

The kallikrein-kinin system: current and future pharmacological targets.

Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A.

J Pharmacol Sci. 2005 Sep;99(1):6-38. Review.

20.

The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.

Kaur P, Muthuraman A, Kaur M.

ACS Chem Neurosci. 2015 Apr 15;6(4):508-21. doi: 10.1021/cn500363g. Epub 2015 Feb 24. Review.

PMID:
25680080

Supplemental Content

Support Center